AEON Biopharma
IRVINE, CA · Biopharma, Biotechnology, Healthcare · 9 employees
AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP
Funding history
- Funding Round — $15.0M — Mar 2024
- Funding Round — $30.0M — Aug 2022
- Funding Round — $30.0M — Aug 2022
- Funding Round — $30.0M — Aug 2022
- Funding Round — $30.0M — May 2021
Recent signals
- Mar 09, 2026: AEON Biopharma Appoints John Bencich as Chief Financial Officer
- Apr 22, 2025: AEON Biopharma Appoints Rob Bancroft as Chief Executive Officer
- Mar 21, 2024: Raised $15.0M
- Aug 11, 2022: Raised $30.0M
- Aug 11, 2022: Raised $30.0M
- Aug 03, 2022: Raised $30.0M
- May 13, 2021: Raised $30.0M
- Aug 31, 2020: Raised $25.0M
See plans & pricing → Track AEON Biopharma’s funding, hiring, and signals — with verified contacts — on Fundz.